Atossa Therapeutics Inc (NASDAQ: ATOS) kicked off on Friday, up 5.70% from the previous trading day, before settling in for the closing price of $0.89. Over the past 52 weeks, ATOS has traded in a range of $0.55-$1.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 36.92% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -16.25%. With a float of $129.12 million, this company’s outstanding shares have now reached $129.17 million.
In an organization with 15 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 26.47%. The most recent insider transaction that took place on May 21 ’25, was worth 9,887. In this transaction President & CEO of this company bought 11,239 shares at a rate of $0.88, taking the stock ownership to the 13,898 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 10,000 for $0.70, making the entire transaction worth $7,000. This insider now owns 10,257 shares in total.
Atossa Therapeutics Inc (ATOS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.47% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Take a look at Atossa Therapeutics Inc’s (ATOS) current performance indicators. Last quarter, stock had a quick ratio of 12.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.8 million. That was inferior than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.71%.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 74.58%, which indicates a significant decrease from 86.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0507 in the past 14 days, which was lower than the 0.0546 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8622, while its 200-day Moving Average is $0.9841. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $0.9749. Second resistance stands at $1.0112. The third major resistance level sits at $1.0587. If the price goes on to break the first support level at $0.8911, it is likely to go to the next support level at $0.8436. The third support level lies at $0.8073 if the price breaches the second support level.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
The company with the Market Capitalisation of 121.23 million has total of 129,170K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -25,500 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,720 K.
